28 results
Irritable Bowel Syndrome (IBS) in Pregnancy
 - Pathophysiology
 - Pharmacotherapy
 - Nonpharmacological Treatment

Emory Gastroenterology and Hepatology
Irritable Bowel Syndrome ... (IBS) in Pregnancy ... Nonpharmacological Treatment ... and Hepatology ... #diagnosis #gastroenterology
Myelodysplastic Syndrome (MD) - Diagnosis and Management Summary
myelo (marrow) -dys- (abnormal) -plastic (shape) = funny-shaped cells
Myelodysplastic Syndrome ... cell transplant is ... only curative treatment ... #Management #treatment ... #hematology #oncology
Irritable Bowel Syndrome (IBS) - Management
Global IBS Symptoms:
  - Limited trial low FODMAP diet
Irritable Bowel Syndrome ... and Hepatology ... Irritable #Bowel #Syndrome ... #Management #gastroenterology ... #treatment
Irritable Bowel Syndrome (IBS) - Diagnosis and Management Summary
Diagnosis:
 • Use a positive diagnostic strategy with
Irritable Bowel Syndrome ... (IBS) - Diagnosis ... IBS is NOT a diagnosis ... and Hepatology ... #treatment
Thrombotic Microangiopathy - TTP VS HUS

Big picture points : Often hard to differentiate the two entities,
distinction has HUGE treatment ... and first-line treatment ... is plasma exchange ... thrombocytopenia #Comparison #Diagnosis ... #Table #Hematology
Approach to Thrombocytosis - Elevated Platelet Count - Differential Diagnosis Algorithm

Peripheral Smear concerning for malignancy?
→ Refer to hematology ... Rebound effect from treatment ... Vasculitides, IBD ... Kawasaki, Nephrotic syndrome ... #Algorithm #hematology
Irritable Bowel Syndrome (IBS) - Diagnosis and Workup Summary
Use a positive diagnostic strategy with minimal testing.
Irritable Bowel Syndrome ... (IBS) - Diagnosis ... IBS is NOT a diagnosis ... and Hepatology ... #gastroenterology
Aplastic Anemia - Overview

Who?
• M = F
• 3 peaks:	1) Childhood	2) 15-25 years	3) >60 years

What?
• Aplastic anemia
- Parvovirus B19 ... of CD34+ cells is ... aplastic anemia Treatment ... Aplastic #Anemia #oncology ... #hematology #diagnosis
Differentiation Syndrome in APML
Epidemiology:
 • Incidence: common in APL (2-48% depending on the study)
 • Triggers:
Differentiation Syndrome ... Triggers: ATRA treatment ... Renal Failure Treatment ... #management #hematology ... #oncology
(DOAC interactions) Cancer-treatment specific inducers (↑) and inhibitors (↓)
of cytochrome p450 CYP3A4 and P-glycoprotein.

DOACs are substrates
interactions) Cancer-treatment ... P-glycoprotein is ... #Chemotherapy #Oncology ... #Hematology #Interactions ... #Table #Pharmacology